[[Tideglusib]]

CATEGORIES: Alzheimer's disease research, Naphthalenes, Thiadiazoles

Tideglusib (NP-12, NP031112) is a potent, selective and irreversible[tpl]cite journal|title=Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3 by Tideglusib|journal=The Journal of Biological Chemistry|date=January 2012|volume=287|issue=2|pages=893–904|doi=10.1074/jbc.M111.306472|pmid=22102280|pmc=3256883|author=Domínguez, JM; Fuertes, A; Orozco, L; del Monte-Millán, M; Delgado, E; Medina, M|url=http://www.jbc.org/content/287/2/893.full.pdf[/tpl] small molecule non-ATP-competitive GSK3 inhibitor that has been investigated as a potential treatment for Alzheimer's disease and 
paralysis supranuclear palsy in Phase IIa[tpl]cite journal | doi = 10.1016/j.jalz.2010.05.455 | title = Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor | year = 2010 | last1 = Teodoro Del Ser | journal = Alzheimer's & Dementia | volume = 6 | issue = 4 | pages = S147[/tpl] and IIb clinical trials.[tpl]cite journal | pmc = 3204427 | last1 = Eldar-Finkelman | first1 = H | last2 = Martinez | first2 = A | title = GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS | volume = 4 | pages = 32 | doi = 10.3389/fnmol.2011.00032 | journal = Frontiers in Molecular Neuroscience | year = 2011 | pmid = 22065134[/tpl][tpl]cite journal | doi = 10.3233/JAD-2012-120805 | pmid = 22936007 | year = 2013 | last1 = Del Ser | first1 = T | last2 = Steinwachs | first2 = KC | last3 = Gertz | first3 = HJ | last4 = Andrés | first4 = MV | last5 = Gómez-Carrillo | first5 = B | last6 = Medina | first6 = M | last7 = Vericat | first7 = JA | last8 = Redondo | first8 = P | last9 = Fleet | first9 = D | last10 = León | first10 = T | title = Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: A pilot study | volume = 33 | issue = 1 | pages = 205–15 | journal = Journal of Alzheimer's disease| doi_brokendate = 2014-03-22 | display-authors = 8 [/tpl][tpl]cite web | title = FDA Grants Fast Track Status to Tideglusib (ZentylorTM) for Progressive Supranuclear Palsy | publisher = PR Newswire Europe Including UK Disclose | date = 10 September 2010 | accessdate = 11 August 2013 | url = http://search.proquest.com/docview/750175748[/tpl][tpl]cite journal | doi = 10.1074/jbc.M111.306472 | title = Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3  by Tideglusib | year = 2011 | last1 = Dominguez | first1 = JM | last2 = Fuertes | first2 = A | last3 = Orozco | first3 = L | last4 = Del Monte-Millan | first4 = M | last5 = Delgado | first5 = E | last6 = Medina | first6 = M | journal = Journal of Biological Chemistry | volume = 287 | issue = 2 | pages = 893–904 | pmid = 22102280 | pmc = 3256883[/tpl] The first clinical trial conducted with tideglusib to be published (in English, at least) was phase II and demonstrated that overall tideglusib was well tolerated, except for some moderate, asymptomatic, fully reversible increases in liver enzymes (≥2.5xULN; where ULN=Upper Limit of Normal).

==Reference List==


